Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.